Medipet Dog Fresh Breath Foaming Mousse 150ml

Product Information

Adults and children over 16 years: 100 to 1,000 micrograms twice daily, usually as two twice daily inhalations. Chronic: refer to section 4.4: risk of adrenal suppression. Monitoring of adrenal reserve may be indicated. Treatment with inhaled fluticasone propionate should be continued at a dose sufficient to control asthma. Some patients feel unwell in a non-specific way during the withdrawal phase despite maintenance or even improvement of the respiratory function. They should be encouraged to persevere with inhaled fluticasone propionate and to continue withdrawal of systemic steroid, unless there are objective signs of adrenal insufficiency. Under normal circumstances, low plasma concentrations of fluticasone propionate are achieved after inhaled dosing, due to extensive first pass metabolism and high systemic clearance mediated by cytochrome P450 3A4 in the gut and liver. Hence, clinically significant drug interactions mediated by fluticasone propionate are unlikely. Administration of doses above 1000 micrograms (500 micrograms twice daily) should be via a spacer device to help reduce side-effects in the mouth and throat. (See section 4.4)

Due to the risk of systemic effects, doses above 500 micrograms twice daily should be prescribed only for adult patients with severe asthma where additional clinical benefit is expected, demonstrated by either an improvement in pulmonary function and/or symptom control, or by a reduction in oral corticosteroid therapy (see sections 4.4 and 4.8). Hoarseness and candidiasis of the mouth and throat (thrush) occurs in some patients. Such patients may find it helpful to rinse out their mouth with water after using the inhaler. Symptomatic candidiasis can be treated with topical anti-fungal therapy whilst still continuing with Flixotide Evohaler.

Excesses

The management of asthma should follow a stepwise programme, and patient response should be monitored clinically and by lung function tests. Administration of high doses, above 1000 mcg daily is recommended through a spacer to reduce side effects in the mouth and throat. However, as systemic absorption is largely through the lungs, the use of a spacer plus metered dose inhaler may increase drug delivery to the lungs. It should be noted that this could potentially lead to an increase in the risk of systemic adverse effects. A lower dose may be required. (See section 4.2) After the two-year training, MediPIET graduates are considered experts in applying epidemiological methods and provide evidence to guide public health interventions for communicable disease prevention and control. Medi-Pet Kit has been changed from providing your Companion with 6 Health per second and 72% Bleedout Reduction, to providing 12 Health per second and reducing Incapacitation time by 15 seconds.

Co-treatment with other potent CYP3A inhibitors, including cobicistat-containing products, is expected to increase the risk of systemic side-effects. Fluticasone propionate given by inhalation at recommended doses has a potent glucocorticoid anti-inflammatory action within the lungs, resulting in a reduction of both symptoms and exacerbations of asthma, with a lower incidence and severity of adverse effects than those observed when corticosteroids are administered systemically.

Acute: Inhalation of the drug in doses in excess of those recommended may lead to temporary suppression of adrenal function. This does not necessitate emergency action being taken. In these patients treatment with fluticasone propionate by inhalation should be continued at a dose sufficient to control asthma adrenal function recovers in a few days and can be verified by measuring plasma cortisol. Vaccines DHP, KC, FeLV, RCP, Myxo RHD PLUS. Vaccinations can include primary three-course (at 8, 12 and 16 weeks), lapsed restart course, boosters excluding rabies. As your cat grows through kitten stages and into adulthood, their health needs change and develop. Staying on top of vaccinations, flea and worm treatments is made easier with the Medivet Healthcare Plan. Key Features

There have been very rare reports of increases in blood glucose levels, in patients with or without a history of diabetes mellitus (see section 4.8). This should be considered in particular when prescribing to patients with a history of diabetes mellitus. After approximately a week, gradual withdrawal of the systemic steroid is commenced. Decrements in dosages should be appropriate to the level of maintenance systemic steroid, and introduced at not less than weekly intervals. For maintenance doses of prednisolone (or equivalent) of 10 mg daily or less, the decrements in dose should not be greater than 1mg per day, at not less than weekly intervals. For maintenance doses of prednisolone in excess of 10 mg daily, it may be appropriate to employ cautiously, larger decrements in dose at weekly intervals. The starting dose should be appropriate to the severity of the disease. The dose should be titrated down to the lowest dose at which effective control of asthma is maintained. Toxicology has shown only those class effects typical of potent corticosteroids, and these only at doses greatly in excess of that proposed for therapeutic use. No novel effects were identified in repeat dose toxicity tests, reproductive studies or teratology studies. Fluticasone propionate is devoid of mutagenic activity in vitro and in vivo and showed no tumorigenic potential in rodents. It is both non-irritant and non-sensitising in animal models. No evidence of impairment of fertility occurred in fertility studies in male and female rats at subcutaneous doses of fluticasone propionate up to 50 mcg/kg/day (approximately 6 times the human exposure associated with the maximum recommended daily inhaled dose of 500 mcg twice daily (110 pg/mL), based on rat plasma levels of approximately 650 pg/mL).As with all inhaled corticosteroids, special care is necessary in patients with active or quiescent pulmonary tuberculosis. If patients find that relief with short-acting bronchodilator treatment becomes less effective or they need more inhalations than usual, medical attention must be sought. Flixotide Evohaler is not designed to relieve acute symptoms for which an inhaled short-acting bronchodilator is required. Patients should be advised to have such rescue medication available.

Not all pet insurance is the same – there are many different types of policy available, and the level of cover they provide varies. It is recommended that the height of children receiving prolonged treatment with inhaled corticosteroids is regularly monitored. If growth is slowed, therapy should be reviewed with the aim of reducing the dose of inhaled corticosteroid, if possible, to the lowest dose at which effective control of asthma is maintained. In addition, consideration should be given to referring the patient to a paediatric respiratory specialist. Many children's asthma will be well controlled using the 50 to 100 microgram twice daily dosing regime. For those patients whose asthma is not sufficiently controlled, additional benefit may be obtained by increasing the dose up to 200 micrograms twice daily. pet stroller and etc. We have our research team to expand and upgrade our product by searching new product and our customer needed. We are not just distribute our house brand, we also looking for other partner to distributed their product. We have been distributed many other item under their brand, and become a vital partner. We distributed under the brand "Cuddles", As with other inhalation therapy, paradoxical bronchospasm may occur with an immediate increase in wheezing after dosing. Flixotide Evohaler should be discontinued immediately, the patient assessed and alternative therapy instituted if necessary.

Our Services

Patients should be made aware of the prophylactic nature of therapy with inhaled fluticasone propionate and that it should be taken regularly even when they are asymptomatic. Sudden and progressive deterioration in asthma control is potentially life-threatening and consideration should be given to increasing corticosteroid dosage. In patients considered at risk, daily peak flow monitoring may be instituted. Fostering country commitment, ownership, and regional networking for the sustainability of the programme.